title: [CORRECTION OF BILE FLOW CHARACTERISTICS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE IN COMBINATION WITH HYPERURICEMIA].
abstract: Basis on study through integrated comparative assessment of clinical, biochemical survey data revealed that in patients with impaired metabolism of uric acid in a greater percentage of common biliary sludge, a violation of the rheological properties of bile, a violation of cholate-cholesterol ratio index, which indicates an increased risk of bile stones. The study found that despite the high levels of uric acid there is a violation of the spectrum of bile acids, cholic and deoxycholic growth acid reduction taurocholic acid. Thus, application of ursodeoxycholic acid, rosuvastatin and allopurinol in these study patients with NAFLD dosages in combination with hyperuricemia improves the clinical symptoms and normalization of biochemical parameters and normalizes the spectrum of biliary acids.
authors.forename: O V
authors.initials: OV
authors.lastname: Barabanchyk
authors.forename: A S
authors.initials: AS
authors.lastname: Svintsits'kyĭ
authors.forename: N P
authors.initials: NP
authors.lastname: Kozak
mesh_terms: D000328:Adult; D000493:Allopurinol / Q000627:therapeutic use*; D001646:Bile / Q000737:chemistry; D002756:Cholagogues and Choleretics / Q000627:therapeutic use*; D002780:Cholestasis, Intrahepatic / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D002784:Cholesterol / Q000378:metabolism; D019826:Cholic Acid / Q000378:metabolism; D003840:Deoxycholic Acid / Q000378:metabolism; D004359:Drug Therapy, Combination; D004384:Duodenoscopy; D005260:Female; D005464:Fluorobenzenes / Q000627:therapeutic use*; D006801:Humans; D033461:Hyperuricemia / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D008099:Liver / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D065626:Non-alcoholic Fatty Liver Disease / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D011743:Pyrimidines / Q000627:therapeutic use*; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides / Q000627:therapeutic use*; D013656:Taurocholic Acid / Q000378:metabolism; D014527:Uric Acid / Q000378:metabolism; D014580:Ursodeoxycholic Acid / Q000627:therapeutic use*
chemical_list: D002756:Cholagogues and Choleretics; D005464:Fluorobenzenes; D011743:Pyrimidines; D013449:Sulfonamides; D003840:Deoxycholic Acid; D014527:Uric Acid; D013656:Taurocholic Acid; D000493:Allopurinol; D014580:Ursodeoxycholic Acid; D000068718:Rosuvastatin Calcium; D002784:Cholesterol; D019826:Cholic Acid